Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial
- 27 October 2009
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 75 (6) , 928-935
- https://doi.org/10.1002/ccd.22340
Abstract
Objective: To explore clinical and bleeding outcomes in patients enrolled in the SYNERGY trial who had percutaneous coronary intervention (PCI) based on adherence to the dosing regimens of enoxaparin mandated by the protocol. Background: In SYNERGY, 4,687 patients underwent PCI during index hospitalization. Patients in the subcutaneous (sc) enoxaparin group were to be given an 0.3 mg/kg IV bolus immediately before PCI if balloon inflation occurred ≥8 hr after their last sc dose of enoxaparin. Methods: The incidence of the 1° efficacy end point (death/myocardial infarction [MI] post PCI and through 30 days), and the rates of post‐PCI in‐hospital TIMI major and GUSTO severe bleeding were compared between patients randomized to unfractionated heparin (UFH) and those randomized to sc enoxaparin who did or did not receive a supplemental IV bolus of enoxaparin in accord with protocol‐mandates. Results: A total of 4,687 patients had PCI; 2,323 were assigned sc enoxaparin and 1,332 received protocol‐mandated IV enoxaparin bolus, while 215 enoxaparin patients received inappropriate IV therapy (either receiving IV enoxaparin before the 8‐hr protocol time or not receiving the IV enoxaparin as directed after 8 hr). Death or MI occurring post PCI through 30‐day follow‐up tended to be lower in the enoxaparin patients who were treated according to protocol than in those who were not (12.3% vs. 14.4%; adjusted P = 0.25), as was TIMI major bleeding (3.0% vs. 4.7%, adjusted P = 0.08). Conclusion: These exploratory analyses show that patients in SYNERGY who received the protocol‐mandated supplemental IV bolus of 0.3 mg/kg enoxaparin before PCI performed 8–12 hr after their last sc enoxaparin dose tended to have improved outcomes compared with those who did not. Strategies to ensure adherence to dosing guidelines of enoxaparin during PCI should be considered.Keywords
This publication has 14 references indexed in Scilit:
- Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY TrialJournal of General Internal Medicine, 2008
- Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparinCatheterization and Cardiovascular Interventions, 2007
- Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trialAmerican Heart Journal, 2006
- ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary ArticleCirculation, 2006
- Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and AspirinA Randomized Controlled TrialJAMA, 2004
- Degree of Anticoagulation after One Subcutaneous and One Subsequent Intravenous Booster Dose of Enoxaparin: Implications for Patients with Acute Coronary Syndromes Undergoing Early Percutaneous Coronary InterventionJournal of Thrombosis and Thrombolysis, 2004
- Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) studyCatheterization and Cardiovascular Interventions, 2004
- Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study11Guest Editor for this manuscript was David A. Vorchheimer, MD, Mount Sinai Medical Center, New York, NY.American Heart Journal, 2003
- Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina PectorisCirculation, 2001
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997